With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Trump threatened "very high" tariffs on Denmark amid Greenland dispute, raising fears of higher prices for Danish pharmaceuticals.

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...